Company intelligence / Profile preview

Laboratori Guidotti

Ownership: Private
Employees: ~499
Development stage: Other

Overview

Laboratori Guidotti specializes in pharmaceuticals and food supplements with a strong presence in chronic respiratory diseases (COPD/asthma), cardiovascular/metabolic disorders including hypertension and diabetes mellitus, as well as lipid management. The company has developed small molecule drugs such as rociverine for gastrointestinal spasm and idrapril for cardiovascular conditions. Some products have achieved market approval internationally while others were discontinued or remain under development. It operates under high quality standards with GMP/FDA-inspected facilities.

Therapeutic areas: NeurologyPulmonologyGastroenterologyEndocrinologyOtherCardiovascular
Modalities: Small moleculeBiologic (inferred from pharma manufacturing focus)Food supplement
Industry: Biotech

Drug pipeline

4 assets

GLIBOMET

3 more assets in the full pipeline.

Beyond the preview

Go deeper on Laboratori Guidotti.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Laboratori Guidotti.